|Table of Contents|

Detection of Treg and Th17 level in peripheral blood of multiple myeloma and its clinical value

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 01
Page:
90-95
Research Field:
Publishing date:

Info

Title:
Detection of Treg and Th17 level in peripheral blood of multiple myeloma and its clinical value
Author(s):
FENG Ruiting; SONG Yinsen; ZHAO Jizhi; QIN Na; MEN Yingli
The Research Center for Translational Medicine,Zhengzhou People’s Hospital,Henan Zhengzhou 450003,China.
Keywords:
multiple myeloma; Treg; Th17; Foxp3; RORγt; clinical value
PACS:
R738.1
DOI:
10.3969/j.issn.1672-4992.2025.01.015
Abstract:
Objective:To detect Treg and Th17 in peripheral blood of patients with multiple myeloma and study their clinical value.Methods:Multiple myeloma patients (MM group) and normal healthy people (CON) were selected as research subjects.Peripheral blood Treg and Th17 were detected by flow cytometry,and Foxp3 and RORγt were detected by real-time fluorescence quantitative PCR (RT-qPCR).Compare the differences in Treg,Th17,Foxp3 and RORγt in different clinicopathological characteristics.The ROC curve was used to analyze the sensitivity and specificity of Treg combined with Th17 in predicting poor 1-year prognosis in multiple myeloma.Multivariate Cox regression analysis of risk factors for death in multiple myeloma.Results:Treg,Th17,Foxp3 and RORγt in the MM group were higher than those in the CON normal healthy people,and the difference was statistically significant (P＜0.05).Treg,Th17,Foxp3 and RORγt in ISS stage III,r-ISS stage III,MRD+ multiple myeloma patients were significantly higher than those in ISS stage I to II,r-ISS stage I to II,and MRD- patients with multiple myeloma (P＜0.05).The sensitivity,specificity and AUC of Treg combined with Th17 in predicting poor 1-year prognosis of multiple myeloma were higher than those of Treg,Th17,Foxp3,RORγt,ISS stage,r-ISS stage,and minimal residual disease (P＜0.05).Treg≥8.23%,Th17≥3.05%,Foxp3≥1.12,RORγt≥0.94,ISS stage III,r-ISS stage III,minimal residual disease MRD+ are independent risk factors for death in patients with multiple myeloma (P＜0.05).Conclusion:Treg and Th17 are significantly increased in patients with multiple myeloma,which are closely related to the condition and prognosis.They can be used as markers for the assessment of the condition and prognosis of multiple myeloma.The combined detection of the two can significantly improve the prediction sensitivity and specificity of multiple myeloma.

References:

［1］ SONNEVELD P,DIMOPOULOS MA,BOCCADORO M,et al.Daratumumab,bortezomib,lenalidomide,and dexamethasone for multiple myeloma［J］.N Engl J Med,2024,390(4):301-313.
［2］ GU Y,BARTOLOM-CASADO R,XU C,et al.Immune microniches shape intestinal T(reg) function［J］.Nature,2024,628(8009):854-862.
［3］ SABREEN G,RAHMAN K,GUPTA R,et al.Role of miRNAs in T-cell activation and Th17/Treg-cell imbalance in acquired aplastic anemia［J］.Int J Lab Hematol,2024,46(3):515-522.
［4］ WANG J,GAO Y,YUAN Y,et al.Th17 cells and IL-17A in ischemic stroke［J］.Mol Neurobiol,2024,61(4):2411-2429.
［5］ MOSCVIN M,EVANS B,BIANCHI G.Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions［J］.J Cancer Metastasis Treat,2023,9:17.
［6］ 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南（2020年修订）［J］.中华内科杂志,2020,59(5):341-346.Chinese Medical Doctor Association Hematology Branch,Chinese Medical Association Hematology Branch,Chinese Medical Doctor Association Multiple Myeloma Professional Committee.Chinese guidelines for the diagnosis and treatment of multiple myeloma (2020 revision) ［J］.Chinese Journal of Internal Medicine,2020,59(5):341-346.
［7］ 张玉丽,范锐,隋华.肠道微生态调控下的Th17/Treg细胞失衡及其在结直肠癌中的作用［J］.现代肿瘤医学，2022,30(09):1684-1689.ZHANG Yuli,FAN Rui,SUI Hua.The imbalance of Th17/Treg under the regulation of intestinal microecology and its role in colorectal cancer［J］.Modern Oncology,2022,30(09):1684-1689.
［8］ 王欢,尼罗帕尔·吐尔逊,赵芳，等.JAK-STAT信号通路与骨髓增生异常综合征Th17/Treg细胞免疫失调相关性的研究［J］.现代肿瘤医学，2022,30(10):1826-1831.WANG Huan,Niluopaer Tuerxun,ZHAO Fang,et al.Study on the correlation between JAK-STAT signaling pathway and immune dysregulation of Th17/Treg cells in myelodysplastic syndrome［J］.Modern Oncology,2022,30(10):1826-1831.
［9］ 张蓝方,张明娟,许进秀,等.PD-1/PD-L1通路、Th17和Tregs细胞在肿瘤免疫中的作用［J］.现代肿瘤医学，2023,31(18):3519-3523.ZHANG Lanfang,ZHANG Mingjuan,XU Jinxiu,et al.Role of PD-1/PD-L1 pathway,Th17 and Tregs cells in tumor immunity［J］.Modern Oncology,2023,31(18):3519-3523.
［10］ ARJOMANDNEJAD M,KOPEC AL,KEELER AM.CAR-T regulatory (CAR-Treg) cells:Engineering and applications［J］.Biomedicines,2022,10(2):287.
［11］ DU J,WANG Q,YANG S,et al.FOXP3 exon 2 controls T(reg) stability and autoimmunity［J］.Sci Immunol,2022,7(72):eabo5407.
［12］ WATANABE T,ISHINO T,UEDA Y,et al.Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity［J］.Cancer Sci,2023,114(5):1859-1870.
［13］ JOSHUA DE,VUCKOVIC S,FAVALORO J,et al.Treg and oligoclonal expansion of terminal effector CD8(+) T cell as key players in multiple myeloma［J］.Front Immunol,2021,12:620596.
［14］ VERKLEIJ C,BROEKMANS M,VAN DUIN M,et al.Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma［J］.Blood Adv,2021,5(8):2196-2215.
［15］ 秦娜,冯睿婷,王璇,等.初诊多发性骨髓瘤外周血PLR与Treg、Th17的相关性及对预后的影响［J］.中国实验血液学杂志,2023,31(6):1757-1763.QIN N,FENG RT,WANG X,et al.Correlation between peripheral blood PLR with Treg,Th17 in newly diagnosed multiple myeloma and its influence on prognosis［J］.Journal of Experimental Hematology,2023,31(6):1757-1763.
［16］ 张丽红,王宣,尹婉宜,等.多发性骨髓瘤患者骨髓单个核细胞Treg、Th17和血清IL-6、IL-10与临床分期以及治疗效果的关系分析［J］.现代生物医学进展,2022,22(14):2713-2717.ZHANG LH,WANG X,YIN WY,et al.Relationship between bone marrow mononuclear cell Treg,Th17,serum IL-6 and IL-10 and clinical stage and therapeutic cffect in patients with multiple myeloma［J］.Progress in Modern Biomedicine,2022,22(14):2713-2717.
［17］ 余方方,吴艳秋,黄翠,等.多发性骨髓瘤患者化疗后近期病死的影响因素及外周血Th17/Treg、NLR对化疗后近期病死的预测价值［J］.广西医学,2023,45(2):129-133.YU FF,WU YQ,HUANG C,et al.Influencing factors for post-chemotherapy short-term mortality in patients with multiple myeloma and predictive value of peripheral blood Th17/Treg,NLR on post-chemotherapy short-term mortality［J］.Guangxi Medical Journal,2023,45(2):129-133.
［18］ LAD D,HUANG Q,HOEPPLI R,et al.Evaluating the role of Tregs in the progression of multiple myeloma［J］.Leuk Lymphoma,2019,60(9):2134-2142.
［19］ 邢健,鲁光,刘国强,等.多发性骨髓瘤患者骨髓中Treg/Th17细胞失衡研究［J］.中国实验血液学杂志,2014,22(5):1321-1325.XING J,LU G,LIU GQ,et al.Imbalance of Treg/Th17 in bone marrow of patients with multiple myeloma［J］.Journal of Experimental Hematology,2014,22(5):1321-1325.
［20］ 刘洪秀,韩艳秋.CAR-NK细胞治疗血液肿瘤的研究进展［J］.临床血液学杂志,2023,36(1):76-80.LIU HX,HAN YQ.Outlook for CAR-NK immunotherapy in hematological malignancy［J］.Journal of Clinical Hematology,2023,36(1):76-80.
［21］ 高勇,于萍,韩姝坤,等.Th9、Th17和Treg细胞及其细胞因子在初诊多发性骨髓瘤中的研究［J］.中国输血杂志,2021,34(8):840-843.GAO Y,YU P,HAN SK,et al.Th9,Th17,Treg cells and their related cytokines in primary diagnosis of multiple myeloma［J］.Chinese Journal of Blood Transfusion,2021,34(8):840-843.
［22］ 潘鑫,王娟,徐冬云,等.Galectin-9在多发性骨髓瘤患者Th17/Treg失衡中的意义［J］.国际检验医学杂志,2022,43(8):1006-1009.PAN X,WANG J,XU DY,et al.Significance of Galectin-9 in Th17/Treg imbalance in patients with multiple myeloma［J］.International Journal of Laboratory Medicine,2022,43(8):1006-1009.
［23］ RAJKUMAR SV.Multiple myeloma:2022 update on diagnosis,risk stratification,and management［J］.Am J Hematol,2022,97(8):1086-1107.
［24］ SOEKOJO CY,CHNG WJ.Treatment horizon in multiple myeloma［J］.Eur J Haematol,2022,109(5):425-440.
［25］ BOUSSI LS,AVIGAN ZM,ROSENBLATT J.Immunotherapy for the treatment of multiple myeloma［J］.Front Immunol,2022,13:1027385.

Memo

Memo:
河南省医学科技攻关计划联合共建项目（编号：LHGJ20220779,LHGJ20210707）;河南省郑州市医疗卫生领域科技创新指导计划项目（编号：2024YLZDJH273）
Last Update: 1900-01-01